newsfilter
← Latest News
GlobeNewswire·

Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026

Six presentations planned, including encore oral presentation of topline X-TOLE2 efficacy and safety resultsNew poster will highlight the mechanistic characterization of azetukalner, including its potential additive